Seres Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $5,958 | $0 |
Gross Profit | -1,059 | -3,527 | 2,979 | -1,404 |
EBITDA | -18,796 | -27,236 | -12,545 | -49,631 |
EBIT | -19,855 | -28,312 | -15,637 | -51,035 |
Net Income | -19,855 | 32,682 | -15,637 | 88,776 |
Net Change In Cash | 0 | 0 | 5,958 | 0 |
Free Cash Flow | -13,470 | 26,876 | -38,972 | -34,809 |
Cash | 45,379 | 58,849 | 30,793 | 66,824 |
Basic Shares | 8,743 | 8,715 | 7,701 | 7,632 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $126,325 | $7,128 | $144,927 |
Gross Profit | -14,698 | 125,621 | 6,124 | 144,927 |
EBITDA | -111,073 | -94,305 | -237,508 | -56,721 |
EBIT | -125,771 | -100,548 | -244,137 | -62,668 |
Net Income | 136 | -113,724 | -250,157 | -65,578 |
Net Change In Cash | 0 | 126,325 | 7,128 | 144,927 |
Cost of Revenue | -16,786 | 71,954 | ||
Free Cash Flow | -148,989 | -125,329 | -238,637 | -2,878 |
Cash | 30,793 | 127,965 | 163,030 | 180,002 |
Basic Shares | 7,770 | 128,003 | 108,077 | 4,585 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$2.27 |
2025-03-31 | -$2.23 |
2024-12-31 | -$0.11 |
2024-09-30 | -$0.33 |
